Back to Journals » Neuropsychiatric Disease and Treatment » Volume 16

CXCL13 Is a Biomarker of Anti-Leucine-Rich Glioma-Inactivated Protein 1 Encephalitis Patients [Response to Letter]

Authors Wang S, Liu X

Received 15 January 2020

Accepted for publication 15 January 2020

Published 30 January 2020 Volume 2020:16 Pages 339—340


Sheng-jun Wang, Xue-wu Liu

Department of Neurology, Qilu Hospital, Shandong University, Ji’nan, People’s Republic of China

Correspondence: Sheng-jun Wang; Xue-wu Liu
Department of Neurology, Qilu Hospital, Shandong University, 107# Wen Hua Xi Road, Ji’nan 250012, People’s Republic of China

Thanks for the concerns and comments of Mr. Zuowei Duan. There were indeed some limitations in our published article since it was only a preliminary exploratory research. As for the rarity of LGI1 encephalitis, only sixteen patients were enrolled in our study. The multifactorial analysis of variance was hard to be evaluated. But we do believe the statistical significance of our finding about the increasing of CXCL13 levels in the patients.
We agree that the clinical significance of CXCL13 levels increasing should not be over-estimated by clinicians. We have stated that the increasing of CXCL13 levels were reported in other autoimmune diseases including multiple sclerosis, neuroborreliosis and anti-NMDAR encephalitis in “Discussion Section” of our published article. The specificity and sensitivity of CXCL13 in serum/CSF for autoimmune encephalitis still need to be further investigated. Anyhow, we have found a potential biomarker for the diagnosis of anti-LGI1 encephalitis.

This is in response to the Letter to the Editor
View the original paper by Lin and colleagues.

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]